Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

At this time, I would like to welcome everyone to the Exact Sciences Third Quarter 2024 ... due to the normal 30-day timing between a Cologuard order and a completed test. Second, disruption ...

Exact Sciences Corp (NASDAQ ... Milton negatively affected Cologuard orders and results, particularly impacting the fourth quarter due to the 30-day timing between order and test completion.

Jefferies analyst Tycho Peterson raised the firm’s price target on Exact Sciences (EXAS) to $85 from $84 and keeps a Buy rating on the ...

“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an ... of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports ...

“Cologuard Plus sets a new performance standard in non-invasive colorectal cancer screening for patients,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “Cologuard Plus detects ...